


**FIG. 1A**

Conjugation Procedure Overview





FIG. 1B

**FIG. 2**




FIG. 3

SEC: mAb302 vs. ADCs comprising the same (ADC-013 & ADC-014)




FIG. 4A

HIC: mAb300 vs. mAb302

WO 2024/197140

6/75

PCT/US2024/020898




FIG. 4B

HIC: mAb300 vs. ADCs comprising the same (ADC-009 & ADC-010)




FIG. 4C

HIC: mAb302 vs. ADCs comprising the same (ADC-013 & ADC-014)




FIG. 4D

DLL3 Biacore Data Fits




FIG. 5

DAR determination




FIG. 6




FIG. 7A




FIG. 7B







FIG. 7C

**FIG. 7D****FIG. 7E****FIG. 7F**




FIG. 7G




FIG. 7H




FIG. 7I




FIG. 7J




FIG. 7K







FIG. 7L

**FIG. 7M****FIG. 7N****FIG. 7O**




FIG. 7P




FIG. 7Q




FIG. 7R




FIG. 8A




FIG. 8B







FIG. 8C

**FIG. 8D****FIG. 8E****FIG. 8F**




FIG. 8G




FIG. 8H




FIG. 8I




FIG. 8J




FIG. 8K







FIG. 8L

**FIG. 8M****FIG. 8N****FIG. 8O**




FIG. 8P




FIG. 8Q






FIG. 8R

**FIG. 9A****FIG.9B**

Compound	Payload	IC ₅₀ (nM)*		Max inhibition	
		72hrs	96hrs	72hrs	96hrs
MMAE		14	19	77%	82%
Exatecan		15	14	74%	78%
ADC-017	MMAE DAR4	5.5	9	64%	67%

* Prism, log(inhibitor) vs response

FIG. 9C




FIG. 9D

Compound	Payload	IC ₅₀ (nM)*	50% inhibition (nM)#	Max inhibition
MMAE		26/27	27	82%
Exatecan		23	26	85%
ADC-015	Exatecan DAR2	ND	>1000	25%
ADC-016	Exatecan DAR4	ND	>1000	39%
ADC-017	MMAE DAR4	3.6	5.4	73%

Signal fold change vs D0 in PBS control: 19

* Prism, log(inhibitor) vs response- Variable slope:

Prism, interpolated mean values

FIG. 9E




FIG. 10A




FIG. 10B




FIG. 10C






FIG. 10D

**FIG. 10E**




Compound	Payload	IC ₅₀ (nM)*	50% inhibition (nM)#	Max inhibition
MMAE		2.5	3.6	93%
Exatecan		3.8	6.4	92%
ADC-015	Exatecan DAR2	ND	612	46%
ADC-016	Exatecan DAR4	824/275	318	62%
ADC-017	MMAE DAR4	48	62	82%

Signal fold change vs D0 in PBS control: 8.5

* Prism, log(inhibitor) vs response- Variable slope

Prism, interpolated mean values

FIG. 11B

**FIG. 11C**


Compound	Payload	IC ₅₀ (nM)*	50% inhibition (nM)#	Max inhibition
MMAE		1.5	2.1	93.4%
Exatecan		2.2	2.8	95.1%
ADC-015	Exatecan DAR2	491	511	44.1%
ADC-016	Exatecan DAR4	ND	353	61.1%
ADC-017	MMAE DAR4	62.4	70.5	83.7%

Signal fold change vs D0 in PBS control: 8.5

* Prism, log(inhibitor) vs response- Variable slope

Prism, interpolated mean values

FIG. 11D

**FIG.11E**


Compound	Payload	IC ₅₀ (nM)*	50% inhibition (nM)#	Max inhibition
MMAE		2.4	2.5	94.8%
Exatecan		2.6	4.7	93.5%
ADC-015	Exatecan DAR2	ND	273	60.7%
ADC-016	Exatecan DAR4	ND	162	71.3%
ADC-017	MMAE DAR4	31.6	22.2	83.9%

Signal fold change vs D0 in PBS control: 8.5

* Prism, log(inhibitor) vs response- Variable slope

Prism, interpolated mean values

FIG. 11F




Compound	Payload	IC ₅₀ (nM)*	50% inhibition (nM)#	Max inhibition
MMAE		3.1	3.9	97%
Exatecan		1.7	1.9	100%
ADC-015	Exatecan DAR2	371	245	69%
ADC-016	Exatecan DAR4	2672/45	99	84%
ADC-017	MMAE DAR4	3.3	6.2	92%

Signal fold change vs D0 in PBS control: 11

* Prism, log(inhibitor) vs response- Variable slope;

Prism, interpolated mean values

FIG. 12B




Compound	Payload	IC ₅₀ (nM)*	50% inhibition (nM)#	Max inhibition
MMAE		4.3	4.5	96.4%
Exatecan		1.5	1.5	99.7%
ADC-015	Exatecan DAR2	110.6	109.5	84.1%
ADC-016	Exatecan DAR4	59.6	48.3	91.9%
ADC-017	MMAE DAR4	18	23.2	90.7%

Signal fold change vs D0 in PBS control: 19

* Prism, log(inhibitor) vs response- Variable slope;

Prism, interpolated mean values

FIG. 12D




Compound	Payload	IC ₅₀ (nM)*	50% inhibition (nM)#	Max inhibition
MMAE		40	39	98.3%
Exatecan		3	3.5	95.4%
ADC-015	Exatecan DAR2	ND	584	45.5%
ADC-016	Exatecan DAR4	ND	127	70.2%
ADC-017	MMAE DAR4	151	NA	15.2%

Signal fold change vs D0 in PBS control: 19

* Prism, log(inhibitor) vs response- Variable slope:

Prism, interpolated mean values

FIG. 13B

**FIG. 14A**

Compound	Payload	IC ₅₀ (nM)*	50% inhibition (nM)#	Max inhibition
MMAE		14.2	14.6	97.8%
Exatecan		3.9	4.1	99.6%
ADC-015	Exatecan DAR2	375.5	496	50.2%
ADC-016	Exatecan DAR4	151.7	162	81%
ADC-017	MMAE DAR4	127	NA	29%

Signal fold change vs D0 in PBS control: 6

* Prism, log(inhibitor) vs response- Variable slope:

Prism, interpolated mean values

FIG. 14B




FIG. 15A




FIG. 15B




FIG. 15C






FIG. 15D

	SHP77		H69		DMS79		CORL279	
Compound	Absolute IC ₅₀ (nM)	Max inhibition	Absolute IC ₅₀ (nM)	Max inhibition	Absolute IC ₅₀ (nM)	Max inhibition	Absolute IC ₅₀ (nM)	Max inhibition
ADC-009	126	34.59%	NA	52.36%	NA	76.09%	369	67.56%
ADC-010	NA	13.36%	40	77.92%	NA	55.07%	NA	75.31%
MMAE	86	89.16%	1.8	96.58%	NA	83.27%	5.2	98.58%

FIG. 15E

**FIG. 16A****FIG. 16B**




FIG. 16C




FIG. 16D




FIG. 16E






FIG. 16F

**FIG. 17A****FIG. 17B**

DAR 4 Isotype ADC 1 mg/kg




FIG. 17C

ADC-015-B 3 mg/kg








FIG. 17D

ADC-015-B 1 mg/kg

**FIG. 17E**

ADC-015-B 0.3 mg/kg x3

**FIG. 17F**

**FIG. 17G****FIG. 17H**

ADC-016-B 1 mg/kg




FIG. 17I

ADC-016-B 0.3 mg/kg x3




FIG. 17J

ADC-016-M 1 mg/kg










FIG. 17K






CXF 742



FIG. 18A**FIG. 18B**



**FIG. 18C****FIG. 18D**



ADC-016-M 5 mg/kg Day(s) 1**FIG. 18E****ADC-016-M 5 mg/kg Day(s) 1,8****FIG. 18F**



ADC-015-M 5 mg/kg Day(s) 1**FIG. 18G****Relative TV: CXF 742 model****FIG. 18H**


**FIG. 18I**


**FIG. 19A****TV: LXFS 2156 model****FIG. 19B**

**FIG. 19C****FIG. 19D**

ADC-016-M 5 mg/kg Day(s) 1**FIG. 19E****ADC-016-M 5 mg/kg Day(s) 1,8****FIG. 19F**

ADC-015-M 5 mg/kg Day(s) 1**FIG. 19G****Relative TV: LXFS 2156 model****FIG. 19H**


**FIG. 19I**







LXFS 573



FIG. 20A

TV: LXFS 573 model

**FIG. 20B**


**FIG. 20C****FIG. 20D**


ADC-016-M 5 mg/kg Day(s) 1**FIG. 20E****ADC-016-M 5 mg/kg Day(s) 1,8****FIG. 20F**

ADC-015-M 5 mg/kg Day(s) 1**FIG. 20G****Relative TV: LXFS 573 model**

- Control Vehicle Day(s) 1,8
- × ADC-016-M 5 mg/kg Day(s) 1
- △ ADC-016-M 5 mg/kg Day(s) 1,8
- ◇ ADC-015-M 5 mg/kg Day(s) 1

FIG. 20H


**FIG. 20I**







CXF 94 LX



FIG. 21A

TV: CXF94 model

**FIG. 21B**


**FIG. 21C****FIG. 21D**


ADC-016-M 5 mg/kg Day(s) 1**FIG. 21E****ADC-016-M 5 mg/kg Day(s) 1,8****FIG. 21F**

ADC-015-M 5 mg/kg Day(s) 1**FIG. 21G****Relative TV: CXF 94 model**


- Control Vehicle Day(s) 1,8
- △ ADC-016-M 5 mg/kg Day(s) 1
- △ ADC-016-M 5 mg/kg Day(s) 1,8
- ◆ ADC-015-M 5 mg/kg Day(s) 1


FIG. 21H

**FIG. 21I**




LXFS 538

FIG. 22A**TV: LXFS 538 model****FIG. 22B**



LXFS 538 D35



- Control Vehicle Day(s) 1,8, N=8
- ▲ ADC-016-M 5 mg/kg Day(s) 1, N=8
- △ ADC-016-M 5 mg/kg Day(s) 1,8, N=8
- ◆ ADC-015-M 5 mg/kg Day(s) 1, N=8


FIG. 22C**LXFS 538 D42**


- Control Vehicle Day(s) 1,8, N=7
- ▲ ADC-016-M 5 mg/kg Day(s) 1, N=8
- △ ADC-016-M 5 mg/kg Day(s) 1,8, N=8
- ◆ ADC-015-M 5 mg/kg Day(s) 1, N=7

FIG. 22D

**FIG. 22E****FIG. 22F**

ADC-016-M 5 mg/kg Day(s) 1,8**FIG. 22G****ADC-015-M 5 mg/kg Day(s) 1****FIG. 22H**

**FIG. 22I**

**FIG. 22J**